Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma? / Specht, Lena; Raemaekers, John; Specht, Lena; Raemaekers, John.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 5, 01.10.2007, p. 881-96.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Specht, L, Raemaekers, J, Specht, L & Raemaekers, J 2007, 'Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?', Hematology/Oncology Clinics of North America, vol. 21, no. 5, pp. 881-96. https://doi.org/10.1016/j.hoc.2007.07.002, https://doi.org/10.1016/j.hoc.2007.07.002

APA

Specht, L., Raemaekers, J., Specht, L., & Raemaekers, J. (2007). Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma? Hematology/Oncology Clinics of North America, 21(5), 881-96. https://doi.org/10.1016/j.hoc.2007.07.002, https://doi.org/10.1016/j.hoc.2007.07.002

Vancouver

Specht L, Raemaekers J, Specht L, Raemaekers J. Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma? Hematology/Oncology Clinics of North America. 2007 Oct 1;21(5):881-96. https://doi.org/10.1016/j.hoc.2007.07.002, https://doi.org/10.1016/j.hoc.2007.07.002

Author

Specht, Lena ; Raemaekers, John ; Specht, Lena ; Raemaekers, John. / Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?. In: Hematology/Oncology Clinics of North America. 2007 ; Vol. 21, No. 5. pp. 881-96.

Bibtex

@article{4d2414304c7c11df928f000ea68e967b,
title = "Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?",
abstract = "The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.",
author = "Lena Specht and John Raemaekers and Lena Specht and John Raemaekers",
note = "Keywords: Disease Progression; Hodgkin Disease; Humans; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic",
year = "2007",
month = oct,
day = "1",
doi = "10.1016/j.hoc.2007.07.002",
language = "English",
volume = "21",
pages = "881--96",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B.Saunders Co.",
number = "5",

}

RIS

TY - JOUR

T1 - Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

AU - Specht, Lena

AU - Raemaekers, John

AU - Specht, Lena

AU - Raemaekers, John

N1 - Keywords: Disease Progression; Hodgkin Disease; Humans; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.

AB - The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.

U2 - 10.1016/j.hoc.2007.07.002

DO - 10.1016/j.hoc.2007.07.002

M3 - Journal article

C2 - 17908626

VL - 21

SP - 881

EP - 896

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 5

ER -

ID: 19370609